How is bupropion used for weight loss, including appropriate dosing, treatment duration, contraindications, and expected efficacy?

Bupropion for Weight Loss

Bupropion monotherapy is NOT FDA-approved for weight loss and should not be used alone for this indication; instead, use the FDA-approved combination of naltrexone-bupropion extended-release (NB-ER), which produces approximately 5-10% weight loss at one year when combined with lifestyle modification. 1

FDA-Approved Formulation

The only bupropion-containing medication approved for weight management is naltrexone 8mg/bupropion 90mg extended-release (NB-ER), approved in 2014 for adults with:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related complication (hypertension, type 2 diabetes, dyslipidemia) 1

Why the Combination Works

Bupropion monotherapy has weak anorectic effects because β-endorphin provides auto-inhibitory feedback on hypothalamic POMC neurons. Naltrexone blocks this negative feedback, allowing bupropion's dopamine and norepinephrine reuptake inhibition to effectively activate anorexigenic pathways and modulate hedonic eating 1.

Dosing Protocol

Titration schedule (critical to minimize adverse effects):

• Week 1: 1 tablet (8mg/90mg) each morning
• Week 2: 1 tablet twice daily (morning and afternoon)
• Week 3: 2 tablets in morning, 1 tablet in afternoon
• Week 4+: Maintenance dose of 2 tablets twice daily (32mg naltrexone/360mg bupropion total daily) 1

Important dosing considerations:

• Take second dose earlier in the day to minimize insomnia risk 1
• Moderate-to-severe renal impairment: Reduce to 1 tablet twice daily 1
• Moderate-to-severe hepatic impairment: Maximum 1 tablet daily 1
• End-stage renal disease: Avoid use 1

Expected Efficacy

At 12 weeks (decision point):

• Discontinue if patient has not lost ≥5% of baseline body weight, as they are likely a poor responder 1

At 56 weeks:

• Mean weight loss: 5.7% with NB-ER vs 2.7% with placebo 2
• Responders achieve mean weight loss of 11.7% 3
• 40-50% of patients lose ≥5% body weight 4
• Real-world data shows 8.8-10% weight loss at 12 months in adherent patients 5

The combination is equally effective in surgery-naive patients and those with weight regain after bariatric surgery 5.

Contraindications

Absolute contraindications:

• Seizure disorder or any history of seizures (bupropion lowers seizure threshold) 6
• Current or recent (within 14 days) MAOI use 7
• Uncontrolled hypertension 7
• Bulimia or anorexia nervosa 7
• Patients requiring short-term or chronic opioid therapy (naltrexone blocks opioid receptors and can precipitate withdrawal or reduce analgesic efficacy) 1
• End-stage renal disease 1

Use with caution in:

• History of depression, anxiety, or suicidal ideation (monitor closely, though studies show no increased risk) 1
• Cardiovascular disease (modest blood pressure increases noted in first 8 weeks) 1

Adverse Effects and Management

Most common reasons for discontinuation (25% vs 10% placebo):

• Nausea (4.6-9.6%)
• Vomiting (0.7-2%)
• Headache (0.9-1.8%)
• Dizziness (0.7-1.4%) 1

Other common effects:

• Insomnia (20% vs 13% placebo) 6
• Dry mouth (20%) 7
• Constipation 1

Mitigation strategies:

• Slow titration reduces adverse effects 7
• Take second dose earlier in day for insomnia 1
• Reduced portion sizes and increased fiber for GI effects 7

Monitoring Requirements

• Blood pressure: Monitor especially in first 8 weeks (modest increases possible, typically resolve by 12 weeks) 1
• Weight: Assess at 12 weeks; discontinue if <5% loss 1
• Psychiatric symptoms: Monitor for depression, anxiety, suicidal ideation (though rates similar to placebo in trials) 1
• Hydration status: If patient takes insulin or sulfonylureas 7

Special Populations

Patients with depression: NB-ER is safe and effective in patients with mild-to-moderate depressive symptoms. Studies show no difference in psychiatric adverse events (27.5% vs 22.1% placebo), depressive symptom increases (9.5% vs 8.8% placebo), or suicidal ideation (1.8% vs 2.0% placebo) 2. Weight loss ≥5% may independently improve mood 4.

Post-bariatric surgery: Real-world data demonstrates equal efficacy in patients with weight regain after bariatric surgery (10% weight loss at 12 months), with 63% adherence at one year 5.

Critical Clinical Pearls

• Never use bupropion monotherapy for weight loss—it lacks FDA approval and has weak efficacy due to unopposed β-endorphin feedback 1
• The 12-week checkpoint is mandatory: discontinue if <5% weight loss achieved 1
• Submaximal doses (if tolerated) can still produce significant weight loss 5
• Must be combined with reduced-calorie diet and increased physical activity 1
• Drug interactions via CYP2B6: ticlopidine/clopidogrel increase bupropion levels; ritonavir/lopinavir/efavirenz decrease levels 6